News
GMAB
29.06
+3.05%
0.86
Genmab Discloses Orbis as New 4.85% Major Shareholder
TipRanks · 16h ago
Genmab Boosted by Strong Q1 2026 DARZALEX Sales of Nearly USD 4 Billion
TipRanks · 19h ago
Johnson & Johnson Q1 Earnings Slip Despite Revenue Growth; Lifts Midpoint Revenue Guidance
NASDAQ · 20h ago
Genmab confirms $3.96B DARZALEX sales in Q1, led by U.S. demand
Seeking Alpha · 20h ago
Analysts Offer Insights on Healthcare Companies: TransMedics Group (TMDX), Stryker (SYK) and Genmab (GMAB)
TipRanks · 21h ago
J&J raises 2026 outlook as oncology products power Q1 beat
Seeking Alpha · 21h ago
Genmab reports Darzalex Q1 worldwide sales $3.964B
TipRanks · 22h ago
DARZALEX Worldwide Net Trade Sales Hit $3.964B In Q1, With US Contributing $2.208B Under Genmab's Exclusive License To J&J
Benzinga · 22h ago
Balancing Strong Near‑Term Execution With Long‑Term Patent and Pipeline Uncertainty at Genmab
TipRanks · 1d ago
Genmab presents safety, tolerability data on Rina-S with bevacizumab
TipRanks · 1d ago
Genmab A/S Reports Phase 1/2 RAINFOL-01 Safety Data For Rinatabart Sesutecan Combo In Advanced Ovarian Cancer, Advances Phase 3 Trial In Platinum-Sensitive Patients
Benzinga · 1d ago
Genmab says Phase 1/2 RAINFOL-01 Rina-S plus bevacizumab shows tolerable safety profile
PUBT · 1d ago
Weekly Report: what happened at GMAB last week (0406-0410)?
Weekly Report · 1d ago
Genmab: Multiple Binaries Could Alter The Thesis
Seeking Alpha · 5d ago
Corbus Offers Upside Despite Post-FDA Update, Analyst Highlights Competitive Edge
Benzinga · 04/07 15:56
Genmab publishes presentation for March 19 annual general meeting in Copenhagen
Reuters · 04/07 07:02
Weekly Report: what happened at GMAB last week (0330-0403)?
Weekly Report · 04/06 09:13
Johnson & Johnson: Success In Multiple Myeloma Underpins $25B In Growth By 2030
Seeking Alpha · 04/04 13:15
Wells Fargo Sticks to Its Buy Rating for Genmab (GMAB)
TipRanks · 04/02 10:59
Genmab Discloses April 1 Vesting of Restricted Stock Units by Top Executives
TipRanks · 04/01 20:24
More
Webull provides a variety of real-time GMAB stock news. You can receive the latest news about Genmab through multiple platforms. This information may help you make smarter investment decisions.
About GMAB
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.